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1416Objectives:Cardiogenic shock still carries a very high mortality.We adopted veno-arterial extracorporeal mem-
brane oxygenation using the Levitronix centrifugal pump (Levitronix LLC, Waltham, Massachusetts) as a first-
line treatment of cardiogenic shock in a ‘‘bridge to decision’’ strategy. This article provides our experience of
this clinical approach.
Methods: Since 1988, 160 ventricular assist devices have been implanted at our hospital for heart failure. Since
2005, 15 consecutive patients have been treated with veno-arterial extracorporeal membrane oxygenation for
refractory cardiogenic shock. Veno-arterial extracorporeal membrane oxygenation has been implanted either
centrally or peripherally.
Results:Mean agewas 44.7 20.0 years (2–78 years). Therewere 5 women. Veno-arterial extracorporeal mem-
brane oxygenation was implanted peripherally in 8 cases (53.4%) and centrally in the remaining 7 (46.6%).
Mean veno-arterial extracorporeal membrane oxygenation duration was 11.5  8.1 days (range, 1–30). No pa-
tient experienced any neurologic event or vascular complication at the cannulation site. Twelve patients (80%)
were weaned from veno-arterial extracorporeal membrane oxygenation or bridged to either a long-term left ven-
tricular assist device or heart transplantation. Three patients died during veno-arterial extracorporeal membrane
oxygenation support secondary to multi-organ failure. Seven patients (46.6%) were discharged from the hospi-
tal, with a 100% survival at follow-up. The survivors include 2 patients affected by fulminant myocarditis, who
were bridged to recovery, and 5 patients who were bridged to heart transplantation. Survivors were younger than
nonsurvivors (mean age, 28.5 vs 58.8 years, respectively).
Conclusions: In our experience, the use of veno-arterial extracorporeal membrane oxygenation as bridge to de-
cision has been effective to promptly restore adequate systemic perfusion, allowing further time to evaluate myo-
cardial recovery or candidacy for ventricular assist device or heart transplantation. Younger patients, with no or
mild end-organ injury, had the best outcomes. Peripheral cannulation decreases the surgical trauma and makes
emergency implantation possible, even in the intensive care unit. (J Thorac Cardiovasc Surg 2010;140:1416-21)Refractory cardiogenic shock (RCS) still carries a very high
mortality.1 In some cases of RCS mechanical circulatory
support (MCS) represents the only therapeutic tool to res-
cue the patient’s life if an intra-aortic balloon pump
(IABP) is not able to provide sufficient cardiac support.
However, uncertainty of patient clinical conditions and
prognosis (ie, reversibility of myocardial damage, end-
organ failure, and possible neurologic impairment), in addi-
tion to the time-pressure imposed by the severity of RCS, as
well as logistical issues (ie, transportability of the patientDe Gasperis Cardiology & Cardiac Surgery Department, Niguarda Ca’
a Hospital, Milan, Italy.
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The Journal of Thoracic and Cardiovascular Surand availability of an operating room), makes the proper
selection of MCS more complex.
At Niguarda Hospital, experience with MCS started in
1988: until July 2009, 160 implants of monoventricular or
biventricular ventricular assist device (VAD) have been
performed. Since 2005, in severely ill patients with RCS re-
quiring emergency MCS, we have been using veno-arterial
extracorporeal membrane oxygenation (VA-ECMO) using
the Levitronix CentriMag centrifugal pump (Levitronix
LLC, Waltham, Mass) as a ‘‘bridge to decision.’’2 In this ar-
ticle, we review our experience in this clinical setting.MATERIALS AND METHODS
We retrospectively reviewed our experience with VA-ECMO for RCS
since 2005. The study was approved by the Hospital Review Board. Be-
tween February 2005 and July 2009, 15 consecutive patients were treated
with VA-ECMO, using a Levitronix CentriMag Blood Pumping System
(Levitronix LLC) as first-line emergency mechanical support for RCS.
All patients were on maximal medical therapy, including at least
two high-dose inotropes, mechanical ventilation, and IABP, if feasible
(Table 1). Profound, rapidly progressing ventricular dysfunction withgery c December 2010
Abbreviations and Acronyms
ACT ¼ activated coagulation time
BSA ¼ body surface area
CS ¼ Cardiogenic shock
HTx ¼ heart transplant
IABP ¼ intra-aortic balloon pump
LV ¼ left ventricle
LVAD ¼ left ventricular assist device
RCS ¼ refractory cardiogenic shock
MCS ¼ mechanical circulatory support
VAD ¼ ventricular assist device
VA-ECMO ¼ veno-arterial extracorporeal
membrane oxygenation
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Xpersistent low blood pressure (systolic blood pressure  80 mm Hg for
adults; 60 mmHg for children) as measured by arterial lines and oliguria
( 0.5 mL/kg/hr) for at least 4 hours despite maximal intropic support and
IABP, which were promptly considered to be an indication for emergent
VA-ECMO implantation. When the implantation was performed in the in-
tensive care unit, all of the ECMO setup was obtained from the operating
room. The Levitronix CentriMag Blood Pumping System is an extracorpo-
real short-term VAD composed of a single-use centrifugal blood pump,
a motor, a console, and a flow probe. The CentriMag motor is based on
bearingless technology that combines the drive, magnetic bearing, and ro-
tor into a single unit. This system can generate flows up to 10 L/minutewith
a priming volume of 31mL, and in Europe the system is licensed for use for
30 days. Alongside the Levitronix CentriMag, we assembled an ECMO cir-
cuit that included a hollow fiber membrane oxygenator, the Quadrox D
(Maquet, Hirrlingen, Germany), and a heater-cooler (Stockert, Munchen,
Germany). If anatomically feasible, a femoral approachwas our first choice
for implantation. For femoral cannulation, we adopted percutaneous arte-
rial (16–20 French) and venous (20–22 French) cannulas (Edwards Life-
science, Irvine, Calif). In 1 case, due to severe femoral artery disease,
the axillary artery was cannulated. Patients were given a bolus of 100
UI/kg of heparin, and after surgical dissection, the proximal common fem-
oral vessels were cannulated. Only in 1 case we inserted the femoral can-
nulas percutaneously. As described elsewhere,3 to allow both to perfuse and
drain of the distal limb, two 6-mm right-angled soft balloon-tipped coro-
nary cannulas for selective anterograde cardioplegia infusion (Maquet,
Hirrlingen, Germany) were inserted, respectively, into the common femo-
ral artery and vein, distally to the main cannulation sites, and secured by
pursestring sutures. Such small cannulas were connected to three-way stop-
cocks to allow both to perfuse and drain the distal limb. The clinical status
of the limb-skin color and temperature (presence of edema) was evaluated
every hour. To prevent thrombosis of distal venous drainage line, it was
flushed with heparinized saline every 2 hours. In case of unfeasibility of
femoral cannulation, because of small or severely atherosclerotic vessels,
or in cases of postcardiotomy shock, we performed a central implant
through standard pursestring sutures placed on the aortic arch and right
atrium. In such case, we adopted a standard aortic cannula (20–22 French;
Edwards Lifescience) and a 2-stage (36/46 French) venous cannula (NGC
Medical Spa, Italy). The speed of the pump was then increased to provide
a pump flow greater than 2.2 L/min/m2. Echocardiography was used to as-
sess cardiac anatomy, ventricular function, and proper venous cannula
placement. We used an IABP4 and low-dose epinephrine5 to reduce after-
load and increase ventricular contractility to unload the left ventricle (LV).
Heparin was infused to maintain an ACTof 160 to 180 seconds for the first
4 days to reduce the incidence of bleeding from the implantation site. After
day 4, heparin dosing was increased to maintain an ACTof 180 to 200 sec-The Journal of Thoracic and Caronds. Close monitoring of hemostasis was performed by means of serial
thromboelastography. End-organ function was closely monitored. Appro-
priate enteral or parenteral nutrition was used.
Weaning From ECMO
In cases in which recovery was expected (fulminant myocarditis or
acute myocardial infarction), weaning was usually first attempted after 4
days of circulatory support, with normal end-organ function. The VA-
ECMO flow was reduced to 500 mL/minute, and provided the LVejection
fraction (EF) of  40% and adequate hemodynamic parameters that were
maintained with low-dose inotropes, from which the patient was weaned
from support. However the weaning trial was discontinued in the case of
unsatisfactory cardiac performance and a new attempt was made the fol-
lowing day.RESULTS
Preoperative and mechanical support data for each pa-
tient are reported in Tables 1 and 2. Mean age was 44.7 
20.0 years (2–78 years) and there were 5 females
(33.3%). The VA-ECMO was implanted peripherally in 8
cases (53.4%) and centrally in the remaining 7 (46.6%).
In 5 cases the implant was performed in the intensive care
unit. In 1 case (6.6%), we resorted to direct left atrial vent-
ing to effectively decompress the left ventricle. Mean time
on ECMO was 11.5  8.1 days (range, 1–30). Full circula-
tory support was achieved in all patients, with flows of up to
5.2 L/minute. Three patients were extubated while undergo-
ing VA-ECMO through femoral cannulation. Overall
preoperative data and outcomes are reported in Table 3.
Bleeding requiring reoperation or more than 6 units of
blood occurred in 4 patients (26.6%) who had a gross coa-
gulopathy. Two patients experienced pulmonary infections,
as diagnosed by culture of bronchial secretions and radio-
logic evidence. No patient experienced any neurologic clin-
ical event, defined as a neurologic deficit permanent or
persistent for more than 24 hours, documented by means
of computed tomography or at necropsy.We did not observe
any mechanical device failure or mechanical hemolysis
(plasma-free hemoglobin > 50 mg/L). Twelve patients
(80%) were weaned fromVA-ECMO or bridged to left ven-
tricular assist device (LVAD) or heart transplant (HTx).
Three patients died (20%) during ECMO support.
Seven patients (46.6%) were discharged from the hospi-
tal, with a 100% survival at follow-up (mean duration of
follow-up, 26.1 months). The VA-ECMO successfully
bridged to recovery 2 patients suffering from fulminant
myocarditis, while the other 5 were bridged to HTx. Survi-
vors were younger than nonsurvivors (mean age, 28.5 vs
58.8 years, respectively) without any differences in length
of ECMO support (mean support, 11 vs 12 days, respec-
tively). Prior to VA-ECMO implantation, both mean serum
creatinine and total bilirubin were higher in nonsurvivors
(1.3  0.4 mg/dL and 1.5  1.0 mg/dL, respectively), as
compared to survivors (1.0  0.5 mg/dL and 1.3  0.9
mg/dL, respectively). The cause of in-hospital death was
multiorgan failure in 6 of 8 cases (75%), pulmonary arterydiovascular Surgery c Volume 140, Number 6 1417
TABLE 1. Patient characteristics before VA-ECMO implantation
Patient Gender Age BSA Etiology Serum creatinine Total bilirubin IABP MV
1 F 34 1.59 Fulminant myocarditis 0.7 0.6 Y Y
2 M 59 1.9 Acute cardiac graft failure 1.0 0.7 Y Y
3 M 65 1.97 Acute myocardial infarction 2.0 1.3 Y Y
4 F 43 1.53 Hypertrophic cardiomyopathy 0.6 0.8 N Y
5 M 78 1.9 Postcardiotomy (MVR) 1.2 1.4 Y Y
6 F 63 1.67 Postcardiotomy (VSR repair) 1.3 0.9 Y Y
7 M 48 1.86 Idiopathic dilated cardiomyopathy 1.3 1.4 Y Y
8 M 33 1.93 Ischemic cardiomyopathy 0.9 2.4 Y Y
9 M 49 1.98 Postcardiotomy (CABG) 1.4 3.7 Y Y
10 M 42 1.57 Idiopathic dilated cardiomyopathy 0.6 2.5 Y Y
11 M 39 1.8 LVAD thrombosis 1.2 1.6 N Y
12 F 17 1.65 Idiopathic dilated cardiomyopathy 0.7 2.8 Y Y
13 F 2 0.5 Fulminant myocarditis 0.8 0.8 N Y
14 M 67 1.8 Postinfarction VSR, s/p CABG 1.9 0.7 Y Y
15 M 32 2.1 Acute myocardial infarction 2.1 0.4 Y Y
BSA is expressed as m2. Serum creatinine and total bilirubin are expressed as mg/dL. BSA, Body surface area; CABG, coronary artery bypass grafting; F, female; IABP, intra-
aortic balloon pump; LVAD, left ventricular assist device; M, male; MV, mechanical ventilation; MVR, mechanical ventilation; N, no; VA-ECMO, veno-arterial extracorporeal
membrane oxygenation; VSR, s/p CABG, ventricular septal rupture in previous CABG; Y, yes.
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Xthrombosis in one case, and fatal thoracic bleeding compli-
cating chest tube insertion in the remaining one. Just before
ECMO support, both mean serum creatinine and total
bilirubin were higher in patients who went on to develop
multi-organ failure (1.37 mg/dL and 1.72 mg/dL, respec-
tively) as compared to remaining patients (1.05 mg/dL
and 1.31 mg/dL, respectively). Necropsy was performed
in 6 cases. In every case, the pathologic findings confirmed
the clinical diagnosis of cause of death. Regarding thrombo-
embolic complications, multiple embolic renal infarctions
were present in 2 patients, thrombosis of small branches
of the pulmonary arteries in 2, massive thrombosis of the
pulmonary artery trunk and multiple pulmonary infarctions
in 1, and splenic infarction in 1. At necropsy, the brain was
examined in only 2 patients, with evidence of mild edema
without ischemic or hemorrhagic lesions.DISCUSSION
Today RCS remains burdened by a very high mortality
rate, despite the use of maximal pharmacologic therapy,
IABP, mechanical ventilation, and continuous veno-venous
hemofiltration. In this setting of severely ill patients, VADs
represent a possible option, either as a bridge to recovery or
HTx.
Unfortunately, mechanical support is not always live
saving. Often the extreme severity and irreversibility of
end-organ dysfunction can not be reversed, despite ade-
quate circulatory support, making VAD implant useless
and cost ineffective in these cases. In the most severe sce-
narios, the chances of recovery are often impossible to pre-
dict at presentation. Although severity of preoperative renal
and liver injury is related to mortality on MCS, as reported
by other authors,6 definite laboratory cut-offs are not yet1418 The Journal of Thoracic and Cardiovascular Suravailable to discriminate consistently between reversible
and irreversible end-organ injury.7 The etiology of cardio-
genic shock is extremely variable, ranging from postcar-
diotomy shock to acute decompensation of chronic heart
failure or acute onset of de novo cardiac failure. The pa-
tients in RCS can be very different from each other and their
conditions are quite variable, and both are related to the pre-
vious health status as well as the duration of cardiogenic
shock. Moreover, some patients can be comatose at presen-
tation making any neurologic assessment very difficult.8
For these reasons the decision making in terms of timing
of implant, type of support (monoventricular or biventricu-
lar) and device selection in such critically ill patients is
quite difficult.
In the very acute scenario, VA-ECMO has several advan-
tages in comparison to more complex circulatory mechani-
cal support such as biventricular VAD. The implantation of
a VAD requires an operating room. Even the transport from
the emergency room of these patients on mechanical
ventilation, inotropes, and IABP can be very risky and
time consuming. Moreover, the significant surgical trauma
associated with VAD implantation has a negative influence
on postoperative mortality and morbidity in very sick
patients.8,9
The ECMO allows for quick institution of full cardiopul-
monary support independent to the extent of cardiac dys-
function (monoventicular or biventricular), stabilizes the
hemodynamic status, and possibly promotes myocardial re-
covery. From a technical point of view femoral cannulation,
when feasible, affords quick VA-ECMO implantation in the
intensive care unit or emergency room. Furthermore, the
surgical trauma of femoral cannulation is less when com-
pared with VAD implantation: the chest is left untouched,
reducing the risk of postoperative bleeding and infectiongery c December 2010
TABLE 2. VA-ECMO support data and outcome
Patient
Implant
site
Pump
speed (rpm)
Pump
flow (L/min)
ECMO
duration (days)
Weaned
from ECMO
Bridge
to HTx
Bridge to
LVAD
Hospital
discharge
1 P 4000 4.1 6 Y Y
2 C 3700 3.6 7 N N
3 C 3300 4.3 18 Y N
4 C 3600 4.6 6 Y Y
5 C 4800 4.0 4 Y N
6 C 4200 4.8 4 Y N
7 P 4000 4.2 16 Y N
8 P 3700 4.4 24 Y Y
9 P 3900 3.9 13 N N
10 P 3800 4.4 4 N N
11 P 4400 5.2 13 Y Y
12 C 3700 4.0 1 Y Y
13 C 2600 2.5 30 Y Y
14 P 3900 4.0 12 Y N
15 P 4200 4.5 15 Y Y
C, Central; ECMO, extracorporeal membrane oxygenation; HTx, heart transplantation; LVAD, left ventricular assist device; N, no; P, peripheral; VA-ECMO, venoarterial extra-
corporeal membrane oxygenation; Y, yes; N, no.
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tation. Finally, when feasible, weaning from mechanical
ventilation is easier and safer in case of peripheral cannula-
tion as compared to central cannulation, as we observed in 3
patients.
Prompt VA-ECMO implant guarantees an extended
‘‘window of observation’’ in stable circulatory conditions.
According to others,8 the stabilization of the patient should
be the primary goal, restoring systemic perfusion with min-
imal risk of complications while preventing malperfusion
damage. During support, the end-organ function, the neuro-
logic status, the chance of myocardial recovery or the indi-
cation to move to further therapies (ie, VAD or HTx) can be
adequately assessed.2,8 The ECMO in RCS appears crucial
for a more rational use of such limited resources, such as
HTx and VAD, by avoiding their adoption in very high-
risk patients who are not going to survive, even on
ECMO, because of severe and irreversible preimplant shock
sequelae.2,6
During the recent years, with improving equipment and
increased experience, ECMO technology has become
more reliable with improved results.10-12 Particularly,
magnetically suspended pumps minimize blood
trauma13,14 and have a very low incidence of mechanical
failure. The Levitronix centrifugal pump is easy to prime,
implant, and manage. It is cheaper than more complex
VADs and reliable for support longer than 6 weeks,
without device-related complications.15,16 Our experience
with Levitronix Centrimag confirms its reliability and the
reported satisfactory outcomes.15-18
When it comes to surgical aspects, the peripheral ap-
proach, instead of a central one, is well suited and should
be considered first in most patients, with the exception ofThe Journal of Thoracic and Carthose with small femoral vessels or in postcardiotomy
shock.
According to other studies,2,6,19 and in our experience,
refractory cardiogenic shock carries still a high hospital
mortality, despite of prompt institution of MCS support.
The mortality reflects the very sick conditions of these
patients. In our series, among survivors there were 2 cases
of fulminant myocarditis and 5 cases successfully bridged
to HTx. However, prognosis in VA-ECMO for postcardiot-
omy shock was dismal. Such observation confirms the re-
sults reported from other groups.5,19 In this study, age and
aetiology were both major determinants of outcome.
Particularly patients with potentially recoverable
conditions, such as fulminant myocarditis and patients
who did not have any underlying condition, which would
contraindicate HTx had better survival outcomes.
Survivors were younger than nonsurvivors (mean age,
28.5 vs 58.8 years, respectively). Preimplant markers of re-
nal and liver injury were slightly higher in nonsurvivors.
Twelve of 15 patients (80%) were weaned from VA-
ECMO or bridged to LVAD/HTx. The mean duration of
VA-ECMO was 11 days, and we did not observe any neuro-
logic complication or device failure during this time. The
most common cause of death was multi-organ failure,
which occurred despite restoration of adequate systemic
blood flow. In these cases, the extreme severity of end-
organ dysfunction could not be reversed, even by adequate
circulatory and respiratory support. As a result, due to the
unpredictability of outcomes, in this group of patients we
assumed that a more complex, invasive, and expensive
MCS system should have not be considered the ‘‘first’’ sup-
port option. The VA-ECMO was implanted as a bridge to
decision, and if necessary it was switched to the implantablediovascular Surgery c Volume 140, Number 6 1419
TABLE 3. Preoperative data and outcome summary
Mean age 44.7  20.0 years (2–78 years)
Female 5/15 (33.3%)
Previous cardiac surgery 2/15 (13.3%)
Postcardiotomy LCOS 3/15 (20.1%)
Pre-ECMO inotropes* 15/15 (100%)
Pre-ECMO MV 15/15 (100%)
Pre-ECMO IABP 12/15 (80.0%)
Peripheral cannulation 8/15 (53.4%)
Central cannulation 7/15 (46.6%)
Direct LV venting 1/15 (6.6%)
Mean ECMO duration 11.5  8.1 days (1–30 days)
Patients weaned from ECMO 4/15 (26.6%)
Patients bridged to HTx 6/15 (40.0%)
Patients bridged to LVAD 2/15 (13.3%)
Patients weaned or bridged to other 12/15 (80.0%)
Mortality on ECMO 3/15 (20.1%)
Patients discharged form the hospital 7/15 (46.6%)
ECMO, Extracorporeal membrane oxygenation; HTx, heart transplantation;
IABP, intra-aortic balloon pump; LCOS, low cardiac output syndrome; LVAD, left
ventricular assist device; LV, left ventricle;MV, mechanical ventilation. *Intravenous
epinephrine, infusion rate more than 0.09 mcg/kg/min.
Cardiothoracic Transplantation Russo et al
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XVAD and/or HTx in patients without cardiac recovery
provided full hemodynamic, neurologic, and end-organ
function recovery had taken place.
Technical solutions for potential drawbacks of peripher-
ally implanted VA-ECMO deserve discussion. In small
body surface area (BSA) patients, particularly young
females, the diameter of femoral vessels can be too small
for cannulation. In our experience, in only 2 cases (ie, 2
females with BSA, ranging between 1.5 and 1.6 m2) we pro-
ceeded to a central implant, following an initial attempt at
peripheral cannulation, because of the small diameter of
the femoral vessels. In 1 patient we cannulated the right ax-
illary artery for arterial return because of severe atheroscle-
rosis of the femoral vessels. An increased risk of early and
late vascular complications following peripheral cannula-
tion for VA-ECMO are reported.20,21 Huang and
colleagues22 suggested that a mean pressure less than
50mmHg into the superficial femoral artery is an indication
to the placement of a catheter for distal perfusion. However,
little attention has been devoted to the risk of severe venous
stasis following femoral vessels cannulation. Restoring the
limb perfusion by means of an additional arterial cannula
may even precipitate venous stasis, particularly if the
venous cannula completely obstructs the distal common
femoral vein. To avoid such a complication, we recommend
our technique of distal limb perfusion and drainage during
VA-ECMO.3 With this technique we did not observe any
limb complications during peripheral VA-ECMO and no
vascular reconstruction of the femoral vessels after
decannulation was required.
Left ventricular decompression during VA-ECMO is of
paramount importance to promote myocardial recovery1420 The Journal of Thoracic and Cardiovascular Surand to prevent pulmonary edema. Retrograde arterial perfu-
sion, aortic valve regurgitation, partial drainage of the right
heart, and bronchial arterial flow are contributing factors in
causing left ventriclular distension, particularly if the ven-
tricle itself is unable to eject. Moreover, distension and
blood stasis inside the left ventricle could lead to formation
of thrombus that may embolize. For these reasons, some de-
gree of left ventricular ejection should be maintained during
support. Although not uniformly agreed,2 we recommend
IABP4 and low-dose epinephrine5 to achieve left ventricle
decompression, by promoting afterload reduction and
increased contractility. Beneficial effects of IABP during
nonpulsatile circulatory support have been reported.4,23
Moreover, diastolic pressure augmentation improves
coronary perfusion, contributing to myocardial recovery.
Serial echocardiographic monitoring of the left ventricle
is mandatory to evaluate LV unloading during support.
Finally, we observed at autopsy several cases of pulmo-
nary and systemic thromboembolism, similar to the experi-
ences reported by Rastan and colleagues.24 In some
instances, thromboembolism has been shown only at the au-
topsy. Clinical underestimation of the thromboembolic bur-
den of MCS is very likely. In our series, despite the absence
of neurologic clinical events, the real rate of cerebral embo-
lism is probably underestimated because of the small num-
ber of brains examined at necropsy. We found macroscopic
clots inside the circuit in 1 case; these were in the oxygen-
ator. The pathogenesis of the thromboembolism is multifac-
torial (ie, blood activation following contact with foreign
surfaces, blood stasis in the cardiac chambers and the sys-
temic veins, disseminated intravascular coagulation, and
pulmonary vascular disease), potentially contributing
mechanisms. These findings underscore the compelling
need for further studies on the prothrombotic state and
appropriate coagulation management during mechanical
circulatory support.
CONCLUSIONS
In our experience, the use of VA-ECMO as bridge to de-
cision has been effective in promptly restoring adequate
systemic perfusion, allowing further time to evaluate myo-
cardial recovery or candidacy for ventricular assist device
or heart transplantation. Younger patients with no or mild
end-organ injury showed the best outcomes. Peripheral can-
nulation decreases the surgical trauma and makes emer-
gency implantation possible, even in the intensive care
unit. Appropriate timing of implant and proper management
on support to avoid complications are warranted to improve
results.
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